Sign In
Buy GMAB
$23.88
+0.0300 (+0.126%)
At Close: Jun 03, 2026
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced new efficacy and safety data from two ongoing Phase 1/2 clinical trials evaluating epcoritamab, a T-cell engaging bispec
Media Release COPENHAGEN, Denmark, and MAINZ, Germany; June 1, 2024 Initial data from the ongoing Phase 2 trial showed a 12-month overall survival (OS) rate of 69% and median overall survival (mOS) of
Transactions in Connection with Share Buy-back Program
10:16am, Monday, 27'th May 2024
Company Announcement COPENHAGEN, Denmark; May 27, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion
Genmab A/S (Nasdaq: GMAB) announced today that multiple abstracts evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, tisotumab vedotin, an antibody-drug conjuga
Genmab Completes Acquisition of ProfoundBio
11:10am, Tuesday, 21'st May 2024
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that it has completed its acquisition of ProfoundBio, Inc., a clinical-stage biotechnology company developing next-gener
Genmab Completes Acquisition of ProfoundBio
11:06am, Tuesday, 21'st May 2024
Company Announcement Genmab has completed acquisition of ProfoundBio for USD 1.8 billion in cash Acquisition gives Genmab worldwide rights to three candidates in clinical development, including rinata
Transactions in Connection with Share Buy-back Program
07:19am, Tuesday, 21'st May 2024
Company Announcement COPENHAGEN, Denmark; May 21, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio
01:34pm, Monday, 20'th May 2024
Fundamentally, one of the biggest advantages of biotech stocks to buy centers on the underlying prioritization. While the media focuses on attaining wealth, that doesn't mean much if you don't have he
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that multiple abstracts evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, will
Media Release COPENHAGEN, Denmark; May 14, 2024 Sixteen abstracts accepted for presentation and publication demonstrate depth and breadth of comprehensive epcoritamab development program Three oral pr
Transactions in Connection with Share Buy-back Program
10:09am, Monday, 13'th May 2024
Company Announcement COPENHAGEN, Denmark; May 13, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion
Capital Increase in Genmab as a Result of Employee Warrant Exercise
02:27pm, Tuesday, 07'th May 2024
Company Announcement COPENHAGEN, Denmark; May 7, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 6,959 shares as a consequence of the exercise of employee warrants. The increase
Transactions in Connection with Share Buy-back Program
10:01am, Monday, 06'th May 2024
Company Announcement COPENHAGEN, Denmark; May 6, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion
Genmab Announces Financial Results for the First Quarter of 2024
11:01am, Thursday, 02'nd May 2024
May 2, 2024 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2024 Highlights The U.S. Food and Drug Administration (U.S. FDA) granted Priority Review for the supplemental Biol
Pfizer, Genmab get full FDA approval for cervical-cancer drug
06:58pm, Monday, 29'th Apr 2024
Pfizer and Genmab on Monday said they had received full approval from U.S. regulators for their treatment for certain forms of cervical cancer.
